Foselutoclax
A BCL-2 inhibitor used in cancer treatment
| Foselutoclax | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Foselutoclax is a small molecule BCL-2 inhibitor that is being investigated for its potential use in the treatment of various types of cancer. It is designed to induce apoptosis in cancer cells by inhibiting the B-cell lymphoma 2 (BCL-2) protein, which is often overexpressed in cancer cells and contributes to their survival.
Mechanism of Action[edit]
Foselutoclax functions by targeting the BCL-2 protein, a key regulator of the apoptosis pathway. BCL-2 is an anti-apoptotic protein that prevents the activation of the apoptotic process, allowing cancer cells to evade programmed cell death. By inhibiting BCL-2, foselutoclax promotes the release of pro-apoptotic factors, leading to the activation of the caspase cascade and subsequent cell death.
Clinical Development[edit]
Foselutoclax is currently undergoing clinical trials to evaluate its efficacy and safety in patients with various hematological malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Early-phase trials have shown promising results, with some patients experiencing significant reductions in tumor burden.
Pharmacokinetics[edit]
The pharmacokinetic profile of foselutoclax is characterized by its absorption, distribution, metabolism, and excretion properties. It is administered orally and has been shown to have a favorable bioavailability. The drug is metabolized primarily in the liver and excreted through the kidneys.
Side Effects[edit]
Common side effects of foselutoclax include nausea, fatigue, and diarrhea. More serious adverse effects can include neutropenia, thrombocytopenia, and tumor lysis syndrome, which require careful monitoring and management during treatment.
Research and Future Directions[edit]
Ongoing research is focused on optimizing the dosing regimen of foselutoclax and exploring its use in combination with other anticancer agents. Studies are also investigating its potential application in solid tumors, expanding its therapeutic scope beyond hematological cancers.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
